Huons Co., Ltd.

Lupin Limited CEO Vinita Gupta thinks the company dodged a bullet as it kept away from the adalimumab race but is positive that a calibrated strategy for other biosimilars could work. Answering a que

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. OcuMension Signs Stock-for-Rights

South Korean pharmas have been actively making investments in bioventures in recent years to find new growth engines. Now, they are taking a step further and joining hands with other pharmas to co-inv

Russia’s attack on Ukraine has become a cause of concern for pharmaceutical companies across the world as parts of the well-oiled machinery that drives drug production, from clinical trials to logisti